Assessment of Aminoglycoside-Induced Hearing Loss Risk in the Perinatal Period
Whitney S. Thompson(Mayo Clinic), Jane E. Brumbaugh(Mayo Clinic), Leslie Saba(University Hospital Galway), Sylvie Girard(Mayo Clinic), Myra Wick(WinnMed), Ellen Bendel‐Stenzel(Mayo Clinic), Linda Hasadsri(Mayo Clinic in Arizona), Lisa A. Schimmenti(University of Minnesota)
Cited by 1
Related Papers
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017
|Journal of the National Comprehensive Cancer Network|2016|660
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|507
Inherited deficiency of the Mac-1, LFA-1, p150,95 glycoprotein family and its molecular basis.
|The Journal of Experimental Medicine|1984|483
Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015
|Journal of the National Comprehensive Cancer Network|2016|293